Tarsus Pharmaceuticals, Inc. TARS Accumulated Depreciation
Accumulated Depreciation at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accumulated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s accumulated depreciation?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accumulated depreciation of $2.3M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accumulated depreciation changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accumulated depreciation increased by 4.5% year-over-year, from $2.2M to $2.3M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accumulated depreciation?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s accumulated depreciation has grown at a 73.4% compound annual growth rate (CAGR), from $134K to $2.1M.
- What does accumulated depreciation mean?
- Total accumulated depreciation on property, plant, and equipment since acquisition — represents the consumed portion of asset useful lives.